[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Patients should expect their providers to ask more medical questions and document more carefully than they did during the shortage years
Bonello, who herself has taken compounded GLP-1 products, says for many patients shes spoken to, the impact of these medications is not just about the weight itself
Found's multidisciplinary intake and dietitian screening may be safer for complex patients
Boye KS, Botros FT, Haupt A, Woodward B, Lage MJ